Gastric bypass surgery is effectively a polypharmacological approach for treatment of obesity, type 2 diabetes and nonalcoholic steatohepatitis (NASH). The gastric bypass mimetic approaches reviewed are fixed-dose combinatorial pharmacological approaches. There are two key concepts incorporated into these gastric bypass surgery mimetic approaches. The first key concept is that the combination of glucagon-like peptide 1 (GLP-1) and fibroblast growth factor 21 (FGF21) is essential for success of any gastric bypass surgery mimetic approach. This combination affords the potential for durable weight loss, glycemic control and reduction in liver lipids. The second key concept is that a fixed-dose combination approach is preferred over post-approval combination of the individual components because the individual components alone often lack sufficient efficacy for development.

胃旁路手术是治疗肥胖，2型糖尿病和非酒精性脂肪性肝炎（NASH）的有效的多药理学方法。审查的胃旁路模拟方法是固定剂量组合药理学方法。这些胃旁路手术模拟方法中包含了两个关键概念。第一个关键概念是胰高血糖素样肽1（GLP-1）和成纤维细胞生长因子21（FGF21）的组合对于任何胃旁路手术模拟方法的成功至关重要。这种组合提供了持久的减肥，控制血糖和减少肝脂质的潜力。